High affinity agonist-binding (HAB) sites are formed from specific receptor interaction with guanine nucleotide-binding (Gi) proteins. To determine whether the release of endothelium-derived relaxing factor (EDRF) is regulated by specific receptor-Gi protein coupling, we treated bovine aortic endothelial cells with 100 ng/ml pertussis toxin (PTX) for 16 hours to effect receptor-Gi protein uncoupling. The degree of receptor uncoupling as measured by the loss of HAB sites for the a2-adrenergic receptor and bradykinin receptor was assessed by radioligand binding studies using partially purified bovine aortic endothelial cell membranes. The release of EDRF in response to UK14304 (an a2-adrenergic receptor agonist) and bradykinin stimulation was measured with a bioassay apparatus. The Gi protein isoforms were characterized by Western blotting, and complete ADP-ribosylation of these proteins was confirmed by PTX-catalyzed [32PINAD ribosylation. PTX produced a greater inhibition of EDRF release via the a2-adrenergic receptor pathway compared with the bradykinin receptor pathway (80%o versus 46%, p<O.Ol). This corresponded to the loss of HAB sites from the c2-adrenergic receptor and bradykinin receptor pathway (72% versus 46%, p<0.01) as compared with complete loss of both HAB sites in the presence of GppNHp (0.1 mM). Since loss of HAB sites from PTX-mediated receptor uncoupling parallels the inhibition of EDRF release, these data suggest that G1 proteins contribute to a greater proportion of HAB sites derived from a2-adrenergic receptor rather than bradykinin receptor interaction and that the inhibition of EDRF release by PTX is mainly due to the loss of these HAB sites. The degree of HAB site formation from specific receptor-G; protein coupling may serve as one mechanism for regulating EDRF release via different cell surface receptors.
fected. 3 Further studies have shown that persistent endothelial dysfunction (i.e., EDRF release) in regenerating porcine coronary arterial endothelium may, in part, be due to abnormalities in receptor-Gi protein coupling.45 None of these studies, however, showed that PTX actually caused receptor-G, protein uncoupling via ADP-ribosylation of the GiQ subunit. Thus, the role of Gi proteins in mediating EDRF release has been implicated but not clearly demonstrated.
One method of assessing receptor-G protein coupling is by determining the presence of high affinity agonist-binding (HAB) sites. These sites are produced as a result of receptor-G protein interaction.6 Such interaction produces a "higher affinity receptor" that is capable of binding agonists with a much lower Kd. This productive interaction between receptor and G protein thereby facilitates the triggering of physiological responses upon hormone binding.78 The purpose of this study, therefore, is to characterize the components of two different receptor-mediated EDRF release pathways and to show that the formation of HAB sites, as a measure of receptor-Gi protein coupling, is differentially involved in EDRF release.
Materials and Methods
Materials
All tissue culture reagents, unless otherwise stated, were obtained from JRH Bioscience. Rabbit anti-factor VIII immunoglobulin was obtained from Accurate Chemical and Scientific Corp., Westbury, N.Y. PTX, indomethacin, phenylmethylsulfonyl fluoride, prostaglandin F2a, (-)-epinephrine, (-)-propranolol, L-phenylephrine, ascorbic acid, calcium ionophore A23187, BK, des-Arg9,[Leu8]-BK, and [Thi5'8,D-Phe7]-BK were purchased from Sigma Chemical Co., St. Louis, Mo. Prazosin, an a1-adrenergic antagonist, and UK14304, an a2-adrenergic agonist, were gifts from Pfizer, Groton Nuclear, Boston. Rauwolscine was obtained from Roth, FRG. Oxymetazoline was obtained from Schering Corp., Bloomfield, N.J. Idazoxan was obtained from Reckitt-Colman, Kingston Upon Hull, UK. The polyclonal rabbit antisera P4 and P6 and rabbit anti-endothelin-1 immunoglobulin were raised in our laboratory. The EC/2 and SW/1 antisera were purchased from Du Pont Pharmaceuticals, Wilmington, Del. The Western blotting kit (Enhanced ChemiLuminescence) using horseradish peroxidase and luminol was obtained from Amersham Corp., Arlington Heights, Ill. Immobilon-P was supplied by Millipore Corp., Bedford, Mass. Recombinant ai2 and ai3 were generously provided by Lutz Birnbaumer and Juan Codina, Baylor, Houston, Tex.
Cell Culture
Fresh bovine aortas were obtained at a local slaughterhouse. Bovine aortic endothelial cells (BAECs) were harvested by gentle scraping and placed in a growth medium containing Dulbecco's modified Eagle's medium supplemented with 5 mM L-glutamine (GIBCO Laboratories, Grand Island, N.Y.), 10% fetal calf serum (Hyclone Laboratories Inc., Logan, Utah), and an antibiotic mixture of penicillin (100 units/ml), streptomycin (100 mg/ml), and amphotericin B (250 ng/ml). The cell culture was incubated at 37°C with 5% C02-95% air. A relatively pure BAEC culture (<5% fibroblasts and smooth muscle cells) was obtained after three cell passages and confirmed by a Nomarski optical microscope (x40 objective, model ICM 405, Zeiss), which showed contact inhibition and typical morphological features of endothelial cells (i.e., cobblestone, polygonal appearance) and by immunofluorescence staining using rabbit anti-factor VIII and anti-endothelin antibodies, followed by horseradish peroxidase-labeled goat antirabbit immunoglobulin and aminoethylcarbazole. For the bioassay of EDRF release, the BAECs were scraped from 150 x15-mm gelatin-coated culture dishes and transferred onto 1.5 g (6x 106 beads) of hydrated microcarrier beads coated with denatured collagen (Cytodex 3, Pharmacia) and grown in suspension using a microcarrier culture vessel and stirring system (Bellco Glass). The suspension of cells and beads was initially placed in 100 ml media and stirred at 15 rpm for 2 minutes every 30 minutes for the first 4 hours to allow for optimal seeding of cells onto the beads. The system was then stirred continuously at 20 rpm with 250 ml media until the cells were confluent on the beads (-80 cells per bead), which usually occurred 3-4 days after seeding. All passages were performed with a disposable cell scraper (Costar Corp., Cambridge, Mass.), and only endothelial cells of less than six passages were used. The BAECs were then treated with PTX (100 ng/ml) for 16 hours before any experiment.
Membrane Purification
The BAECs were suspended in ice-cold lysis buffer (0.1 mM phenylmethylsulfonyl fluoride, 5 mM EDTA, 5 mM EGTA, 100 mM NaCI, 5 mM Tris-HCl, pH 7.4), disrupted by a Dounce homogenizer (10 strokes twice), and centrifuged at 40,000g for 30 minutes at 4°C. The crude pellet was washed twice with ice-cold suspension buffer (100 mM Tris-HCl, 5 mM MgCl2, 0.6 mM EDTA, pH 7.4) and then centrifuged at 3,000g for 10 minutes. The pellet was discarded, and the supernatant was centrifuged again at 40,000g for 45 minutes at 4°C. The resulting pellet containing the enriched membrane preparation was then resuspended at a protein concentration of 2-2.5 mg/ml as determined by the method of Lowry et al.9
Characterization of Receptors on Endothelial Cells
Characterization of the a2-adrenergic receptor was performed with the agonist [3H]UK14304 (5 nM) in the presence and absence of prazosin (10 ,uM), rauwolscine (1 ,uM) , or oxymetazoline (1 ,u M) . Nonspecific binding was determined in the presence of (-)-epinephrine (0.1 mM). The reaction mixture (100 gg membrane in a total volume of 100 gl) was allowed to equilibrate at room temperature (23°C) with gentle shaking for 45 minutes. The assays were terminated by rapid filtration on GF/C filters (Whatman Inc., Clifton, N.J.). Each filter was counted for 2 minutes in a liquid scintillation counter (model LS 1800, Beckman Instruments, Inc., Fullerton, Calif.). The binding studies for the BK receptor were performed in a similar fashion with the following exceptions: The buffer, in addition, contained bacitracin (140 ,ug/ml), captopril (1 ,uM, E.R. Squibb & Sons, Inc., Princeton, N.J.), dithiothreitol (1 mM), 1,10-phenanthroline (1 mM), and bovine serum albumin (0.1%). All reaction tubes and filters were pretreated overnight with 0.1% bovine serum albumin and 0.1% polyethylenimine, respectively. Binding of the radioligand, [3H]BK (5 nM) was competed with 10 ,uM des-Arg9,[Leu8]-BK (a BK1 antagonist) or 10 ,uM [Thi58,D-Phe7]-BK (a BK2 antagonist) at 4°C for 90 minutes. Nonspecific binding was determined in the presence of BK (1 ,uM) .
EDRF Bioassay
The EDRF bioassay apparatus consisted of an openperfusion system, a mounted ring assembly attached to a force transducer for measuring vascular tension, and bioassay tissues. The system was constantly perfused at 4 ml/min by a roller pump (Minipuls 2, Gilson) with modified Krebs-Ringer bicarbonate solution of the following concentration (mM): NaCl 118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25.0, EDTA 0.026, and glucose 11.1. The solution was aerated with 95% 02-5% CO2 and kept at 37°C by means of a thermocirculator (Lauda MS, Brinkmann Instruments, Inc., Westbury, N.Y.).
Adult male Sprague-Dawley rats (Charles River Breeding Laboratories, Wilmington, Mass.) weighing 200-250 g were killed by decapitation. After removal of the aortas, the adherent loose connective and adipose tissues were dissected away. The endothelium was removed by gently rubbing the lumen with a dry cotton swab. The denuded aorta was then cut into 4-mm cylindrical strips and mounted on a bioassay ring connected to an isometric force transducer (model FTO3C, Grass Instrument Co., Quincy, Mass.). Changes in iosometric force resulting from relaxation or contraction of the bioassay tissue were recorded on a polygraph (model BD 41, Kipp & Zonen, Bohemia, N.Y.). In addition to the main perfusion port (4 ml/min), the denuded aorta was also directly perfused with Krebs' solution through a second port at 2 ml/min. The total perfusion reaching the smooth muscle bioassay tissue was 6 ml/min. In a stepwise manner, the aorta was passively stretched until maximum contractions were obtained with repeated stimulation by KCI (80 mM). Preliminary studies showed that 1 g of tension was the optimal passive tension for isolated rat aortic rings.
To eliminate the effects of prostanoids, we added indomethacin (10 4liM) to the perfusate, and the stretched artery was allowed to equilibrate for 60 minutes. Active tension (70% maximal contraction, 1.8-2.0 g) was produced by the addition of L-phenylephrine (5 gM) with ascorbic acid (0.1 mM) or, in some cases, prostaglandin F2a (4 ,uM) to the second infusion port. The bioassay ring was then allowed to reach steady state (45 minutes). Before all experiments, both calcium ionophore A23187 and the agonist of interest were infused through the second port to determine whether these agents alone could directly elicit smooth muscle relaxation. Any bioassay tissue that relaxed in response to these agents was discarded. Several samples of denuded aorta were also examined by light and electron microscopy to assess the degree of endothelial removal. Approximately 6 x 106 endothelial cells confluent on microcarrier beads were pretreated with PTX or buffer before being packed into a 70-,um chromatographic filter column (Evergreen Scientific Co.). The columns were perfused via the main port with modified Krebsindomethacin solution. The BAECs were stimulated to release EDRF by UK14304 (from 10`10 to 10-5 M), BK (from 10`to 10`6 M), and A23187 (from 10-10 to 10-5 M) administered into the perfusate proximal to the main port by means of an infusion pump (model 901, Harvard Apparatus, South Natick, Mass.) at a rate of 0.2 ml/min. The release of EDRF was monitored as a decrease in bioassay ring tension and expressed as percent relaxation of active tension. Confirmatory evidence for EDRF release was obtained by the addition of methylene blue (10 ,uM) and hemoglobin (10 ,uM), substances that are known to inhibit the effects of EDRF, to the perfusate of the second port. Similarly, superoxide dismutase (150 units/ml) was added to the second infusion port to determine whether it potentiated the effects of EDRF. Initial studies using UK14304, the a2-adrenergic agonist, were performed in the presence of (-)-propranolol (0.1 mM), prazosin (0.1 mM), and ascorbic acid (0.1 mM) with prostaglandin F2a. (4 ,uM) used to produce active tension. Preliminary results showed no effect of prazosin on UK14304 -stimulated EDRF release; hence, later studies used L-phenylephrine (5 ,uM) to produce active tension (administered via the second infusion port) in the absence of prazosin. Specific activation of the a2-adrenergic receptor by UK14304 was demon-strated by infusing the a2-adrenergic receptor antagonists (rauwolscine [0.1 uM], oxymetazoline [0.1 lM], or prazosin [1 ,M]) directly onto the bioassay tissue (via the second infusion port) so as to block UK14304 stimulation. The specific BK receptor antagonists, des-Arg9,[Leu8]-BK (1 ,uM) and [Thi58,D-Phe7]-BK (1 MM), were infused via the second port during BK stimulation to determine which receptor subtype was being activated by BK.
Radioligand Binding Studies
Similar binding conditions previously outlined for the a2-adrenergic receptor and BK receptor were used. Radioligand binding studies for the a2-adrenergic receptor were performed with [3H]rauwolscine or [3H]UK14304 at 12 concentrations ranging from 10-12 to Proteins from partially purified BAEC membranes (50 jtg) and various known amounts of recombinant Ca2 and ai3 were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10% running, 4% stacking gel) according to the method of Laemmli.10
The proteins were electrophorectically transferred onto Immobilon-P and incubated overnight at 4°C with the specific antisera. The Immobilon-P was washed twice with blocking solution (100 mM NaCL, 10 mM Tris-HCl, 1 mM EDTA, 1% Nonidet P-40, 2.5% bovine serum albumin fraction V, 2.5% nonfat dry milk, 0.00002% NaN3, pH 8.0) and exposed to goat anti-rabbit horseradish peroxidase antibody before autoradiography at 23°C for 1 minute. To determine that the 40-kd protein recognized by P4 antisera was the result of a specific interaction with Gi,.2, we performed initial Western blots with an excess of the specific peptide, KENLKDCGLF, to the P4 antisera to demonstrate that we could block this reaction.
ADP-Ribosylation With [32P]NAD in BAEC Membrane Preparations
The protocol was derived from the method of Ribeiro-Neto et al"l with some modifications. Partially purified membranes (100 jig) from rat brain and PTXtreated and -untreated BAECs were suspended in dithiothreitol (2 mM), Tris-HCI (25 mM), EDTA (1 mM), GTP (0.5 mM), ATP (1 mM), thymidine (10 mM), DNase 1 (0.02 ,ug/ml), bovine serum albumin (7.5 ug per assay), and Lubrol-PX (1%) in a total volume of 100 ul.
The reaction was begun with the addition of [32P]NAD (60 ,uM) and preactivated PTX (10 gug/ml). Preliminary studies using unlabeled NAD (60 ,uM) followed by [32P]NAD (60 gM) indicated that complete ADP-ribosylation is achieved after 2 hours at 32°C. The reaction was terminated with 1 ml ice-cold trichloroacetic acid (20%) and centrifuged at 12,000g for 10 minutes. The resulting pellets containing ADP-ribosylated G proteins were then resolubilized in denaturing buffer containing Tris-HCl (125 mM, pH 6.8), SDS (4%), glycerol (20%), and 2-mercaptoethanol (10%) and placed in boiling water for 5 minutes. The samples and known molecular weight markers (Bethesda Research Laboratory) were separated by SDS-PAGE (10% running, 4% stacking gel) before autoradiography at -70°C for 72 hours.
Data Analysis
All values including graphic depictions with error bars are expressed as mean ±SEM compared with controls and among separate experiments. The radioligand binding studies were analyzed by the methodology of Scatchard12 and the LiGAND program of Munson and Rodbard. 13 The EDRF bioassays were performed simultaneously for each condition and its control. Paired and unpaired Student's t tests were used to determine the significance of shifts in Ki, Kd, and EC50 and changes in specific binding and isometric tension (EDRF release). A significant difference was taken for values ofp<0.05.
Results

Cell Culture and Bioassay Tissue
Relatively pure BAEC cultures were confirmed by immunofluorescent staining with factor VIII antibodies. Endothelin antibodies also stained these cells. There were no observable adverse effects of PTX (100 ng/ml, 16 hours) on cellular morphology, growth, or immunofluorescent staining. Deendothelialized rat thoracic aorta failed to relax directly in response to A23187, UK14304, and BK, indicating functional removal of the endothelium. Light and scanning electron microscopy also revealed the absence of endothelial cells in adjacent rubbed aortic segments used in the bioassay experiments (photographs not included).
Characterization of Receptors on Endothelial Cells
Specific binding of [3H]UK14304 to BAEC membranes was completely blocked by rauwolscine (1 gM), partially blocked by oxymetazoline (1 ,uM), and not blocked by prazosin (10 ,uM) ( Figure 1A ). This is consistent with the a2-adrenergic receptor subtype (10 ,uM) , indicating that the predominant BK receptor in BAECs is the BK2 subtype ( Figure 1B ).
Scatchard and LIGAND analysis of [3H]rauwolscine saturation showed one binding site with a Kd of 1.7±0.2 nM and a Bma of 200±19 fmol/mg. Nonspecific binding at 5 nM of [3H]rauwolscine with excess unlabeled (-)-epinephrine was 58±7 fmol/mg. However, [3H]UK14304 saturation binding studies revealed the existence of two classes of binding sites: an HAB site (94±16 fmollmg) with a K, of 0.22±0.07 nM and a low affinity site (110±14 fmol/mg) with a K, of 1.40±0.05 nM (Figure 2A) . With the addition of GppNHp, only one affinity site (200±13 Similarly, [3H]BK saturation binding studies also revealed two classes of binding sites: an HAB site (34±2.7 fmol/mg) with a K1 of 16±+1.3 pM and a low affinity site (82+9.3 fmol/mg) with a K1 of 780+67 pM ( Figure 2B ). 40±3.7 nM, indicating that BK was acting via the BK2 receptor ( Figure 3B ). Calcium ionophore A23187 elicited relaxation with an EC50 of 20±3.2 nM and was not affected by rauwolscine or [Thi58,D-Phe7]-BK. Forskolin (1 ,uM) and 8-bromo-cAMP (0.1 mM) did not inhibit UK14304-stimulated release of EDRF, indicating that this a2-adrenergic receptor effect was not mediated via decreases in intracellular cAMP levels (data not shown).
Effects of PTX on EDRF Release
Pretreatment of BAECs with PTX caused a decrease in maximal relaxations to both UK14304 and BK. There was no further inhibition of EDRF release with pretreatment of PTX as high as 300 ng/ml and as long as 36 hours. The release of EDRF in response to UK14304 was more sensitive than BK to treatment with PTX, with Maximal inhibition of relaxation is greater with UK14304 than bradykinin. There were only small shifts in the EC50 with both agonists. Note that most of the endothelium-derived relaxing factor release via UK14304 stimulation is mediated by pert ussis toxin-sensitive Gproteins (Giproteins), whereas more than half of the endothelium-derived relaxing factor release via bradykinin stimulation occurs via pertussis toxin-insensitive G proteins or mechanism(s) independent of G proteins. greater inhibition of relaxation (80% versus 43%, p<0.01) (Figure 4 ). There was no further inhibition of EDRF release by PTX at concentrations >100 ng/ml (data not shown). Treatment with PTX caused small rightward shifts of the EC50 for both UK14304 (from 26+2.8 to 34±3.3 nM,p<0.05) and BK (from 1.2+0.2 to 1.6±0.3 nM, p<0.05). Compared with control conditions, there was no effect of PTX on the response to calcium ionophore A23 187 (maximum inhibition, 3.4+4.2%; EC50, 26±4.3 nM;p=NS).
Effects of PTX on Receptor-Gi Protein Coupling
Treatment with PTX produced a loss of HAB sites to both a2A-adrenergic receptors and BK2 receptors at 
Identification of G Protein Subtypes and Isoforms
Western blot analysis of BAEC membranes with the P4 and EC/2 antisera revealed single bands of 40 and 39 kd, respectively ( Figure 6 ). Prior treatment with excess Gi2 carboxy-terminal peptide resulted in the loss of the 40-kd band that was previously recognized by the P4 antisera (data not shown). The P6 antisera, which are specific for Giai, failed to recognize a 40-kd protein in BAEC membranes but did recognize a protein of -40 kd in rat brain. The EC/2 antisera also recognized in rat brain a protein of smaller molecular mass (39 kd) that was not present in endothelial cells. Therefore, our data indicate that BAEC membranes contain predominantly Gja2 and Q,3 but little, if any, Gi,l. Because EC/2 antibody may not recognize Go with the same affinity as Gio, we cannot completely exclude the presence of Go in BAECs by Western blotting using this antibody. When known amounts of recombinant ai2 and a1i3 were used as standards on Western blots, the amount of Gia2 and Gia3 in BAEC membranes (100 ,g) was 7.7±0.8 and 2.8±0.5 ng, respectively. This corresponded to 1.9 pmol Gia2 and 0.65 pmol Gi3 per milligram membrane protein. The concentration of the f3 subunit recognized by SW/1 antisera was unchanged in membranes from BAECs treated with PTX (data not included). FIGURE 6. Western blots of membrane proteins (50 p£g) from rat brain (BR) and bovine aortic endothelial cells (EC) incubated with P, (specific for Gi,1), P4 (recognizes both G,ai and Gia, and EC/2 (recognizes Gia3 and Goj) antisera. Molecular masses are expressed in kilodaltons. Bovine aortic endothelial cell membranes contain predominantly Gia2 and Ga3 but little, if any, Giaj and Gaa
Discussion
The release of EDRF in response to UK14304, an imidazoline derivative, appears to be mediated specifically via the a2-adrenergic receptor since its response can be competitively blocked by the specific a2-adrenergic receptor antagonist rauwolscine. 15 The relative insensitivity to high concentrations of prazosin suggests that the probable subtype is a2A. 14 The studies with [32PJNAD-labeled membranes from rat brain revealed several bands: two bands running between 40 and 41 kd, consistent with G, protein(s), and another band running at 39 kd, which may represent Go proteins. In contrast, [32P]NAD-labeled BAEC membranes revealed only a single band running between 40 and 41 kd, suggesting the absence of Go in BAEC membranes. After treatment with PTX, the BAEC membranes no longer contained the substrate for PTXcatalyzed [32P]NAD ribosylation at 40-41 kd, indicating complete ADP-ribosylation of Gi proteins. 28 -FIGURE 7. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of pertussis toxin (PTX) -catalyzed, [32P]NADlabeled, partially purified rat brain and bovine aortic endothelial cell (BAEC) membranes (100 pg) with and without pretreatment of intact BAECs with 100 ng/ml PTX. The 39-kd band in rat brain membrane is consistent with Goa, whereas the two bands running between 40 and 41 kd probably represent Gia,2 and Gia3. Note that the Gi proteins were completely ADP-ribosylated when the intact BAEC was pretreated with PTX at 100 ng/ml for 16 hours. This is representative of three experiments. 46 -4 1 40 39 a_ SIOW 28-labile nonprostanoid substance that was potentiated by superoxide dismutase and inhibited by methylene blue and hemoglobin. This is characteristic of endotheliumderived nitric oxide or a nitric oxide derivative that relaxes vascular smooth muscle by stimulating soluble guanylate cyclase. 17, 18 Our results suggest that the release of EDRF via the a2-adrenergic receptor and the BK receptor is differentially coupled to Gi proteins in BAEC membranes. The a2-adrenergic receptor pathway appears to be more sensitive to PTX with respect to EDRF release compared with the BK receptor pathway since PTX-sensitive Gi proteins and HAB sites account for about 80% of EDRF released via the a2-adrenergic receptor, whereas they account for less than half of the EDRF released via BK receptors. This is consistent with previous findings that BK-stimulated increase in inositol triphosphate turnover and EDRF release in bovine pulmonary artery endothelial cells are relatively insensitive to PTX, although GDP,BS could effectively block this activity.2
Although two distinct binding sites have been reported for the BK receptor in bovine pulmonary artery endothelial cells, it is not known whether the higher affinity site represented G protein-coupled receptors. 19 Similar pharmacological studies with the a2-adrenergic receptor have not been performed in BAECs, although HAB sites for both the a-and ,B-adrenergic receptor resulting from receptor-G protein coupling have been documented in other cell lines.7,8 Receptors binding agonists with high affinity reflect a productive interaction with G proteins.6 These sites are converted to ones of low affinity when uncoupling from their G protein is affected, as by the addition of guanine nucleotides or PTX treatment. The fact that a greater percentage of a2A-adrenergic receptors are coupled to a PTX-sensitive G protein in BAECs may be a function of their preferential coupling to Gi proteins. This is consistent with our finding that more HAB sites are produced and a greater amount of EDRF is released via PTX-sensitive 2Aadrenergic receptor than BK2 receptor pathways.
Receptor-G protein coupling may be influenced by several factors that include receptor phosphorylation, colocalization of receptors and G proteins with putative membrane domains, and the availability of G proteins for receptor coupling. Furthermore, PTX-catalyzed ADP-ribosylation of the ai subunit of G proteins is a complex process whose efficiency is likely determined by stoichiometry, accessibility,20 posttranslational modification,21 and affinity for fly, which is required for efficient ADP-ribosylation.22 It is curious that only 29% of the BK2 receptor population is G protein-coupled in BAEC membranes as compared with -50% of the a2A-adrenergic receptor population. This difference may reflect the differing abilities of these receptors to couple to the repertoire of G proteins available in BAECs. For example, among three Gi protein isoforms previously identified, we have shown that BAEC membranes contain only two of these isoforms, Gia2 and Gia3.23 These isoforms may possess both differential affinities for their receptor(s) and sensitivities to PTX. Hence, the greater percentage of HAB sites observed with the a2A-adrenergic receptor may be due to its more efficient coupling to Gia2, which appears to be the predominant PTX-The a2-adrenergic receptor in BAECs appears to couple rather selectively to Gi proteins in signaling the release of EDRF, whereas the BK2 receptor can effectively couple to both PTX-sensitive and -insensitive G proteins. Such specificity and diversity in signal transduction pathways have been documented in other cell types. Multiple G proteins that activate phospholipase C are selectively coupled to different receptors in Chinese hamster ovary cells and are also distinguished by their PTX sensitivity. 24 The dopamine (D2) receptor selectively couples to Gia2 in reconstituted phospholipid vesicles. 25 Treatment of platelet and neuroblastoma gliomahybridoma cell membranes with specific carboxyterminal-directed Gia2 antisera blocks a2-adrenergic and 8-opioid receptor-mediated inhibition of adenylyl cyclase.2627 Similarly, the release of EDRF can be mediated via diverse transduction pathways with specific receptors either using or sharing distinct G proteins.
In summary, the release of an important physiological vasodilator, EDRF, from BAECs is mediated by selective receptor-G, protein coupling. Our data indicate that EDRF release via the a2A-adrenergic receptor is more closely coupled to Gi proteins than release via BK2 receptors in BAECs, whereas coupling of the BK2 receptor is accomplished predominantly through PTXinsensitive G proteins. Specificity at the level of receptor-Gi protein interaction may provide the endothelial cell with mechanism(s) to modulate EDRF release at or beyond the level of the hormone-receptor interface. These processes that direct the traffic of cell surface signals may involve not only the type of receptor but also the particular Gi protein to which it is coupled. It remains to be determined whether modulation of both the amount and the expression of specific Gi protein isoforms can influence the release of EDRF via these two receptor pathways in endothelial cells.
